Quantcast

Latest Thoratec Stories

2014-09-22 08:28:03

COMPANY PROVIDES THIRD QUARTER FINANCIAL UPDATES PLEASANTON, Calif., Sept. 22, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that D. Keith Grossman has been appointed President and Chief Executive Officer, effective immediately. Mr. Grossman succeeds Gary F. Burbach, who has stepped down from his executive and Board roles but will remain as...

2014-09-09 16:26:44

PLEASANTON, Calif., Sept. 9, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that it has begun to enroll patients in the HeartMate III(TM) U.S. clinical trial. "We are excited to continue our recent pipeline progress with the start of the U.S. clinical trial for HeartMate III," said Gary F. Burbach, President and Chief Executive Officer....

2014-08-29 16:23:53

PLEASANTON, Calif., Aug. 29, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September 10. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 12:55 p.m., Eastern Daylight Time (9:55 a.m., Pacific...

2014-08-06 16:29:25

PLEASANTON, Calif., Aug. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has entered into a $30 million Accelerated Share Repurchase (ASR) agreement. "This commitment to capital deployment reflects our ongoing conviction in the long term opportunities in our business," said Gary F. Burbach, President and Chief Executive Officer....

2014-08-06 16:29:23

PLEASANTON, Calif., Aug. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its CE Mark Clinical Trial for HeartMate PHP(TM) (Percutaneous Heart Pump) has commenced. "We are excited to begin the CE Mark Clinical Trial for HeartMate PHP and look forward to successful execution of this important clinical study," said Gary F. Burbach, President and...

2014-08-06 16:29:13

- Revenue of $118.1 million for the second quarter of 2014 PLEASANTON, Calif., Aug. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the second quarter and first half of 2014. "We are disappointed with the shortfall in our financial results as near-term factors are having a greater than expected negative...

2014-08-04 16:27:06

PLEASANTON, Calif., Aug. 4, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Canaccord Genuity 34(th) Annual Growth Conference on Wednesday, August 13. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 2:00 p.m., Eastern Daylight Time (11:00 a.m., Pacific...

2014-07-21 16:26:19

PLEASANTON, Calif., July 21, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the second quarter of fiscal year 2014 on Wednesday, August 6. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific...

2014-07-02 16:24:45

PLEASANTON, Calif., July 2, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has acquired Apica Cardiovascular Limited ("Apica") for an upfront cash payment of $35 million and potential future clinical and sales milestones of up to $40 million. As part of the agreement, the Apica team based at facilities in Ireland and the United States will...

2014-06-27 08:25:53

PLEASANTON, Calif., June 27, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that its CE Mark Clinical Trial for HeartMate III(TM) commenced with the first patient implanted with this new device. "We are pleased to reach this significant clinical milestone with an important pipeline product," said Gary F. Burbach, President and Chief Executive...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related